{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}],"title":"Number of participants with functional CAR T cell persistence through the Day 63 study assessment"},{"measurements":[{"groupId":"OG000","value":"28"}],"title":"Number of participants without functional CAR T cell persistence through the Day 63 study assessment"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"Participants will be followed for 63 days to determine if the transferred T cells remain detectable in the blood and bone marrow","groups":[{"description":"Participants from the efficacy-evaluable leukemia population who were followed for loss of persistence through the d63 assessment window.","id":"OG000","title":"SCRI-CAR19v1/v1.5 Efficacy- and Persistence-evaluable Leukemia Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy-evaluable leukemia patients in Phase 2, plus Phase 1 patients treated at the Phase 2 dose in Cohort 1F2, who received SCRIv1 or SCRIv1.5 CAR T cells following prescribed lymphodepletion with fludarabine and cyclophosphamide and who were followed for loss of persistence through the Day 63 assessment window. Excludes one participant with insufficient samples collected to determine Day 63 persistence status.","reportingStatus":"POSTED","timeFrame":"Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)","title":"Persistence of Functional CD19 CAR+ T Cells","type":"SECONDARY","unitOfMeasure":"Participants"}